Advertisement
BSX vs ISRG
Which Stock Would AI Choose? Boston Scientific (BSX) vs. Intuitive Surgical (ISRG) Stock Comparison
Key Takeaways
- BSX has delivered stronger year-to-date (YTD) gains of approximately 36%, outperforming ISRG's 20% amid recent market recovery.
- ISRG trades at a premium price-to-earnings (P/E) ratio of 57 versus BSX's more attractive 31, reflecting its specialized growth profile.
- Both stocks hover near the lower end of their 52-week ranges, with BSX close to its floor amid electrophysiology (EP) concerns, while ISRG benefits from da Vinci system momentum.
- Upcoming Q1 2026 earnings for both companies are anticipated to highlight revenue growth, with analysts bullish on BSX's cardiovascular strength and ISRG's procedure expansion.
- BSX offers broader diversification across medical segments, contrasting ISRG's focused robotics dominance.
- Market sentiment favors stability in recent weeks, positioning ISRG with fewer near-term overhangs.
Introduction
Boston Scientific (BSX) and Intuitive Surgical (ISRG) represent key players in the medical technology sector, where innovation drives healthcare delivery. BSX focuses on interventional devices, while ISRG leads in robotic-assisted surgery. This comparison suits investors and traders evaluating relative performance in a sector sensitive to procedural volumes, regulatory shifts, and economic cycles. With both stocks navigating recent volatility near 52-week lows, understanding their business models, momentum, and catalysts provides clarity on market positioning and potential trade-offs in the current environment.
BSX Overview and Recent Performance
Boston Scientific Corporation (BSX) develops medical devices for cardiology, endoscopy, and rhythm management. In recent market activity, shares have traded around $61, near the 52-week low of $60.59 after a sharp pullback from highs above $109, influenced by February 2026 guidance signaling slower electrophysiology (EP) market growth at about 15%. Sentiment dipped on the cautious 2026 outlook, with adjusted earnings per share (EPS) projected at $3.43-$3.49, below some estimates. However, YTD gains exceed 36%, buoyed by robust cardiovascular demand. Analysts remain optimistic, citing potential 30% year-over-year growth in 2026 and strong Q1 revenue expectations of 11% growth. Price targets hover near $90, reflecting confidence ahead of upcoming earnings.
ISRG Overview and Recent Performance
Intuitive Surgical, Inc. (ISRG) dominates robotic-assisted minimally invasive surgery through its da Vinci systems. Shares recently traded around $452-$467, down from a 52-week high of $603 but stable relative to peers, with YTD performance at about 20%. Recent weeks have seen steady momentum from da Vinci 5 adoption and procedure growth projections of 13-15% for 2026, following 18-19% increases in prior quarters. Revenue reached $2.87 billion in Q4 2025, beating estimates, though some caution arises from China market pressures and regulatory scrutiny. High P/E of 57 underscores premium growth expectations, with analysts forecasting EPS expansion. The stock's resilience stems from market leadership and innovation catalysts.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the top 25 performers from over 350 AI trading bots that analyze thousands of tickers across diverse strategies, timeframes, and styles like swing trading, trend following, and volatility plays. These bots showcase impressive stats, including annualized returns ranging from 15% to over 167% (averaging around 65%), win rates of 54-88% (averaging 62%), and profit factors from 1.5 to 11.7. Focused on sectors like semiconductors, energy, and small caps, they adapt to current conditions using technical (TA) and fundamental (FA) analysis. Traders can explore these high-performing options to enhance strategies amid volatile markets. Visit the Trending AI Robots page for real-time insights and potential copy-trading opportunities.
Head-to-Head Comparison
BSX and ISRG both thrive in medtech but diverge in focus: BSX's diversified portfolio spans cardiology and endoscopy for steady organic growth of 10-11%, while ISRG leverages robotics monopoly for higher procedure-driven expansion. Recent momentum favors BSX's YTD outperformance, yet ISRG exhibits greater stability with fewer guidance overhangs. Risk factors include BSX's EP slowdown versus ISRG's regulatory and competitive exposures in China. Valuation trade-offs pit BSX's value at lower P/E against ISRG's growth premium. Sector exposure highlights BSX's breadth buffering cyclicality, contrasting ISRG's concentrated upside.
Tickeron AI Verdict
Tickeron’s AI models currently lean toward ISRG with higher probability for sustained trends, driven by consistent procedure growth, da Vinci catalysts, and relative stability versus BSX's volatility from guidance concerns. While BSX offers compelling value and diversification, ISRG's market positioning edges it in observable momentum factors.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BSX is a Hold and ISRG is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BSX’s FA Score shows that 0 FA rating(s) are green whileISRG’s FA Score has 0 green FA rating(s).
- BSX’s FA Score: 0 green, 5 red.
- ISRG’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BSX’s TA Score shows that 4 TA indicator(s) are bullish while ISRG’s TA Score has 4 bullish TA indicator(s).
- BSX’s TA Score: 4 bullish, 4 bearish.
- ISRG’s TA Score: 4 bullish, 4 bearish.
Price Growth
BSX (@Medical/Nursing Services) experienced а -5.49% price change this week, while ISRG (@Pharmaceuticals: Other) price change was -2.69% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +15.84%. For the same industry, the average monthly price growth was +15.98%, and the average quarterly price growth was -7.93%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.62%. For the same industry, the average monthly price growth was +3.20%, and the average quarterly price growth was -11.86%.
Reported Earning Dates
BSX is expected to report earnings on Jul 29, 2026.
ISRG is expected to report earnings on Jul 16, 2026.
Industries' Descriptions
@Medical/Nursing Services (+15.84% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (-0.62% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| BSX | ISRG | BSX / ISRG | |
| Capitalization | 70.9B | 142B | 50% |
| EBITDA | 5.49B | 3.95B | 139% |
| Gain YTD | -49.984 | -28.086 | 178% |
| P/E Ratio | 19.95 | 49.49 | 40% |
| Revenue | 20.6B | 10.6B | 194% |
| Total Cash | 1.45B | 4.52B | 32% |
| Total Debt | 11B | 87M | 12,644% |
BSX | ISRG | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 61 | 66 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 63 Fair valued | 80 Overvalued | |
PROFIT vs RISK RATING 1..100 | 93 | 63 | |
SMR RATING 1..100 | 58 | 51 | |
PRICE GROWTH RATING 1..100 | 65 | 64 | |
P/E GROWTH RATING 1..100 | 98 | 86 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BSX's Valuation (63) in the Medical Specialties industry is in the same range as ISRG (80). This means that BSX’s stock grew similarly to ISRG’s over the last 12 months.
ISRG's Profit vs Risk Rating (63) in the Medical Specialties industry is in the same range as BSX (93). This means that ISRG’s stock grew similarly to BSX’s over the last 12 months.
ISRG's SMR Rating (51) in the Medical Specialties industry is in the same range as BSX (58). This means that ISRG’s stock grew similarly to BSX’s over the last 12 months.
ISRG's Price Growth Rating (64) in the Medical Specialties industry is in the same range as BSX (65). This means that ISRG’s stock grew similarly to BSX’s over the last 12 months.
ISRG's P/E Growth Rating (86) in the Medical Specialties industry is in the same range as BSX (98). This means that ISRG’s stock grew similarly to BSX’s over the last 12 months.
| BSX | ISRG | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 81% | 1 day ago 68% |
| Stochastic ODDS (%) | 1 day ago 60% | 1 day ago 56% |
| Momentum ODDS (%) | 1 day ago 52% | 1 day ago 60% |
| MACD ODDS (%) | 1 day ago 49% | 1 day ago 69% |
| TrendWeek ODDS (%) | 1 day ago 53% | 1 day ago 62% |
| TrendMonth ODDS (%) | 1 day ago 57% | 1 day ago 68% |
| Advances ODDS (%) | 14 days ago 58% | 7 days ago 68% |
| Declines ODDS (%) | 3 days ago 54% | 3 days ago 59% |
| BollingerBands ODDS (%) | 1 day ago 71% | 1 day ago 63% |
| Aroon ODDS (%) | 1 day ago 66% | 1 day ago 62% |
Advertisement
BSX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BSX has been closely correlated with ISRG. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if BSX jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To BSX | 1D Price Change % | ||
|---|---|---|---|---|
| BSX | 100% | +0.02% | ||
| ISRG - BSX | 71% Closely correlated | +1.24% | ||
| MMSI - BSX | 56% Loosely correlated | -0.39% | ||
| ALC - BSX | 49% Loosely correlated | -0.09% | ||
| NTRA - BSX | 45% Loosely correlated | -0.41% | ||
| A - BSX | 44% Loosely correlated | +1.74% | ||
More | ||||